Canopy Growth and Tilray Brands entered the final months of 2026 with improving revenue trends but sharply different business models. Canopy is concentrating on cannabis, medical markets and its Storz & Bickel vaporizer business, while Tilray is combining cannabis with beverages, pharmaceutical distribution and wellness.
The March acquisition of MTL Cannabis supported flower sales, while a Veterans Affairs Canada reimbursement cut reduced the amount paid to producers for medical cannabis from C$8. 50 to C$6 per gram starting April 1.
The company’s fiscal 2026 results showed the same restructuring pattern. Full-year revenue increased 6% to C$284. 6 million, free-cash outflow improved to C$69. 1 million from C$176. 6 million, and Canopy ended the year with C$131. 3 million in net cash. It still posted a C$20. 2 million adjusted EBITDA loss for the year, but said cost controls and the integration of MTL were expected to support positive adjusted EBITDA during fiscal 2027.
Tilray’s latest quarter was larger and more diversified.
The comparison therefore turns on the type of exposure an investor is seeking. Canopy offers a more concentrated recovery story tied to Canadian medical cannabis, international cannabis growth and operating improvements; Tilray offers greater scale and diversification, with recent growth led by beverages and distribution rather than cannabis alone. Neither company’s latest results establish a definitive “better buy” without considering valuation, dilution, execution and the risks attached to each strategy.